Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administered, selective C5a receptor inhibitor, could replace...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Am Soc Nephrol
Hlavní autoři: Jayne, David R.W., Bruchfeld, Annette N., Harper, Lorraine, Schaier, Matthias, Venning, Michael C., Hamilton, Patrick, Burst, Volker, Grundmann, Franziska, Jadoul, Michel, Szombati, István, Tesař, Vladimír, Segelmark, Mårten, Potarca, Antonia, Schall, Thomas J., Bekker, Pirow
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Nephrology 2017
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5576933/
https://ncbi.nlm.nih.gov/pubmed/28400446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016111179
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky